ReviewDiabetes & metabolism journal2023
Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control.
Review in Diabetes & metabolism journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Harnessing Machine Learning, a Subset of Artificial Intelligence, for Early Detection and Diagnosis of Type 1 Diabetes: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Trial
- Diabetes Educators' Perspectives on MiniMed™ 780G Onboarding: Insights from a Multiregional Survey Across Europe, the Middle East, and Africa.Advances in therapy · 2026Article
- On the road to fully automated insulin delivery: A systematic review of meal announcement free algorithms.PLOS digital health · 2026Article
- Continuous glucose monitoring and risks of acute and chronic diabetes-related complications and mortality in adults with type 1 diabetes: a nationwide cohort study.Diabetologia · 2026Article
- The rebirth of pancreas transplantation: an innovative, fully robotic, reproducible surgical technique.BMC surgery · 2026Review
- Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol (SMART-5 Study).Endocrinology and metabolism (Seoul, Korea) · 2026Article
- Continuous glucose monitoring metrics based clustering in people living with type 1 diabetes identifies phenotypes associated with higher inflammation, metabolic dysfunction-associated steatotic liver disease risk, and lower insulin sensitivity.Diabetology & metabolic syndrome · 2026Article
- Effectiveness of the Stage 4 Smart Insulin Pen DIA:CONN P8 for Glycemic Control in a Real-World Setting.Diabetes & metabolism journal · 2026Article
- Integrating Pharmacists into CGM-Enabled Digital Diabetes Care: Advancing Personalized and Data-Driven Management.Healthcare (Basel, Switzerland) · 2026Review
- Addressing Unmet Needs in the Management of Diabetes in Asia and Enhancing Diabetes Care Through the Use of Digital Technology: An Expert Opinion.Journal of the ASEAN Federation of Endocrine Societies · 2026Review
- Exploring the Potential of Nuciferine in Diabetes ManagementCurrent medicinal chemistry · 2026Article
- Noninvasive subterahertz glucose monitoring using a communication inspired eye diagram.Scientific reports · 2025Article
- Current Status of Continuous Glucose Monitoring Use in South Korean Type 1 Diabetes Mellitus Population-Pronounced Age-Related Disparities: Nationwide Cohort Study.Diabetes & metabolism journal · 2025Article
- Machine Learning-driven Identification of the Honeymoon Phase in Pediatric Type 1 Diabetes and Optimizing Insulin ManagementJournal of clinical research in pediatric endocrinology · 2025Article
- Amperometric Determination of Glucose at Physiological pH by an Electrode Modified with a Composite Ni/Al-Layered Double Hydroxide and Electrochemically Reduced Graphene Oxide.Nanomaterials (Basel, Switzerland) · 2025Article
- Comparison of Real-Time and Intermittently-Scanned Continuous Glucose Monitoring for Glycemic Control in Type 1 Diabetes Mellitus: Nationwide Cohort Study.Diabetes & metabolism journal · 2025Article
- Metabolic interventions as adjunctive therapies to insulin in type 1 diabetes: Current clinical landscape and perspectives.Diabetes, obesity & metabolism · 2025Review
- Abuse-deterrent wearable device with potential for extended delivery of opioid drugs.Biomedical engineering letters · 2025Article
- Personalization of continuous glucose monitoring system for diabetic patients in the Polish market in 2024.Pediatric endocrinology, diabetes, and metabolism · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Continuous glucose monitoring (CGM) technology has evolved over the past decade with the integration of various devices including insulin pumps, connected insulin pens (CIPs), automated insulin delivery (AID) systems, and virtual platforms. CGM has shown consistent benefits in glycemic outcomes in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) treated with insulin. Moreover, the combined effect of CGM and education have been shown to improve glycemic outcomes more than CGM alone. Now a CIP is the expected future technology that does not need to be worn all day like insulin pumps and helps to calculate insulin doses with a built-in bolus calculator. Although only a few clinical trials have assessed the effectiveness of CIPs, they consistently show benefits in glycemic outcomes by reducing missed doses of insulin and improving problematic adherence. AID systems and virtual platforms made it possible to achieve target glycosylated hemoglobin in diabetes while minimizing hypoglycemia, which has always been challenging in T1DM. Now fully automatic AID systems and tools for diabetes decisions based on artificial intelligence are in development. These advances in technology could reduce the burden associated with insulin treatment for diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.